1 / 18

FRCPath Part 1 Self Help Session

FRCPath Part 1 Self Help Session. Trinucleotide Repeat Disorders Helene Schlecht. Various pathogenic mechanisms underlie trinucleotide repeat diseases. With examples discuss how the following mechanisms can cause trinucleotide repeat disease: Loss of function RNA gain of function

svea
Download Presentation

FRCPath Part 1 Self Help Session

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. FRCPath Part 1 Self Help Session Trinucleotide Repeat Disorders Helene Schlecht

  2. Various pathogenic mechanisms underlie trinucleotide repeat diseases. With examples discuss how the following mechanisms can cause trinucleotide repeat disease: • Loss of function • RNA gain of function • Protein gain of function

  3. Introduction • Dynamic trinucleotide mutations are short tandem repeat polymorphisms that above a certain size become unstable. • Mechanism of repeat expansion. • Unclear - Related to parent of origin and timing of expansion during development. • Possible models: loop formation during base excision repair/ nucleotide excision repair; Slippage model; Replication involving lagging strand. McMurray 2010

  4. Introduction • Three pathogenic mechanisms underlying trinucleotide repeat disorders: • Loss of function • RNA gain of function • Protein gain of function

  5. Loss of function • Features – no protein function, other types of mutations have same effect; non coding. • Examples FRAXA, FRAXE and Friedreich ataxia (FRDA)

  6. Loss of function • FRAXA • Fragile X syndrome one of most common forms of inherited mental retardation. • X-linked dominant with reduced penetrance (80% males, 30% females). • Phenotype mild to severe mental retardation, mildly abnormal facial features. • Associated with fragile site A – Xq27.3 • CGG repeat in 5’UTR of FMR1 gene • AGG interuptions • Normal range 7-~60 • Pre mutation ~60-200 – unmethylated, but unstable. • Full mutations >200 repeats – abnormally hypermethylated.

  7. Loss of function • FRAXA – cont. • The expansion causes the CpG island within the promoter region as well as the repeat to become methylated and histone acetylation decreases – leads to transcriptional silencing. • FMR1 gene is widely expressed in human tissues. • FMR1 protein has domains that suggest it’s an RNA-binding protein, which is critical for its function. • Highly expressed in brain neurons and regulates mRNA translation in dendrites, thereby modulates synaptic function. So reduced FMR1 causes mental retardation.

  8. Loss of function Model for FMRP function: A, FMRP dimerizes in cytoplasm, enter nucleus and assembles into mRNP. Transports mRNA into cytoplasm. B, In fragile X patients, get abnormal regulation, localisation or abundance of mRNA.

  9. Loss of function • FRAXE • CCG repeat in 5’UTR of FMR2 gene • Full mutations >200 repeats • Similar mechanism to FRAXA • FMR2 protein is thought to act as a transcription factor, but cellular function and role in disease still unknown. • FRDA Schmucker 2010 • Neurodegenerative disorder. • GAA repeat in intron 1 of FDRA gene. • Recessive • Pre mutation – 34-100; Full mutation 66-1700 • Expansion decreases mRNA levels. 2 models: • Non-B DNA conformation and/or heterochromatin-mediated gene silencing. • Frataxin involved in iron homeostasis. • Frataxin deficiency disrupts iron-sulphur enzymes, mitochondrial iron overload causing iron dysregulation and increased sensitivity to oxidative stress.

  10. RNA Gain of function • Features – no other types of mutations; repeated allele is transcribed, but not translated; non coding. • Examples DM1, DM2, FXTAS, SCA8, 10 and 12 • Myotonic Dystrophy (DM1/2) • DM1 - CTG repeat in 3’UTR of DMPK. • DM2 – CCTG repeat in intron 1 of zinc finger protein 9 (ZNF9). • Two functionally different genes, but same toxic RNA gain of function mechanism.

  11. RNA Gain of function • DM1/2 toxic RNA gain of function mechanism • Almost all of expanded mRNA retained in nuclear foci, due to secondary structures (eg hairpins). • Expanded mRNA can sequester RNA-binding proteins – bind to the (CUG)n (CUG-BP1 and MBNL1). • RNA binding proteins regulate mRNA processing (eg splicing). • DMPK and ZNF9 splicing is normal, but thought expansion causes aberrant expression of other transcripts, normally regulated by CUG-BPs.

  12. RNA Gain of function • Fragile X-associated tremor/ataxia syndrome (FXTAS) • CGG pre mutation carriers (55-200 repeats) in 5’UTR of FMR1. (20% female pre mutation carriers develop premature ovarian failure). • mRNA levels are elevated, but protein levels close to normal – so toxic RNA. • Proposed similar mechanism to DM. • Clear difference with DM is DMPK and ZNF9 normal transcript levels. • ? Larger DM repeats, so more short repeats in FXTAS has same effect. • SCA 8, 10 & 12 • Repeats are in non-coding regions. Mechanism unknown thought to be RNA gain of function.

  13. Protein Gain of function • Features • No other types of mutations • Coding regions • Altered protein by CAG repeat – polyglutamine tract • Neurodegenerative disorders. • Associated with neuronal aggregates containing expanded gene product. • PolyQ tracts become insoluble and form aggregates. • Repeat size threshold similar between disease (~35-40rps). • Examples: Huntington’s disease, Kennedy’s disease (SBMA), DRPLA, SCA 1, 2, 3, 6, 7 & 17

  14. Protein Gain of function • Huntington’s disease • Chorea, incoordination, motor impersistence. • CAG repeat at N terminus of Huntingtin protein. • Protein function – precise function unknown, but does have role in vesicular transport, cytoskeletal anchoring and clathrin-mediated endocytosis. • Loss of function may account for some of pathogenesis in HD, most thought to be protein gain of function. • Mechanism of how inclusions lead to pathology unclear – affects transcription regulation, apoptosis, mitochondrial function, tumour suppression, vesicular and neurotransmitter release and axonal transport.

  15. Protein Gain of function • Kennedy’s disease • Weakness and atrophy of proximal muscles. Difficulties swallowing and articulating speech. • CAG repeat in androgen receptor gene on X chromosome. • Androgen receptor regulates transcription of hormone-responsive genes upon androgen binding. • Expansion causes decrease in protein expression and alter transcriptional activation – causes androgen insensitivity in SBMA patients. • Motor neuron dysfunction due to toxic protein gain of function.

  16. Protein Gain of function • Spinocerebellar ataxias • Expanded CAG repeats seen in SCA 1, 2, 3, 6, 7 and 17. • All SCA gene are different: Ataxin 1-3 and 7, subunit of CACNA1A (SCA 6), TBP (SCA 17). • Disease pathways unclear. • Cannot rule out some polyQ diseases have loss of function effect on pathogenicity.

  17. Keywords • Trinucleotide repeat • Dynamic mutation • Short tandem repeat polymorphisms • Loss of function – absence of transcription • RNA gain of function – toxic RNA – splicing • Protein gain of function – neuronal aggregates.

  18. References • McMurray 2010 – mechanism expansion • Brouwer 2009 – loss of function, gain of function • Jin 2000 – Fragile X • Schmucker 2010 – FRDA • Walker 2007 – HD

More Related